Monopar Therapeutics (MNPR) Return on Capital Employed (2018 - 2025)

Monopar Therapeutics (MNPR) has 7 years of Return on Capital Employed data on file, last reported at 12.57% in Q3 2025.

• For the quarter ending Q3 2025, Return on Capital Employed changed N/A year-over-year to 12.57%; the trailing twelve-month figure through Sep 2025 stood at 12.57% (changed N/A YoY), and the FY2025 full-year result was 8.72%, up 39.0% from the prior year.
• Return on Capital Employed rose to 12.57% in Q3 2025, from 18.57% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 12.57% in Q3 2025 to a low of 131.32% in Q3 2023.
• A 4-year average of 69.73% and a median of 68.1% in 2022 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed sank 328 bps in 2021 and tumbled 5680 bps in 2023, its largest moves.
• Tracing MNPR's Return on Capital Employed over 4 years: stood at 45.78% in 2021, then plunged by 115 bps to 98.41% in 2022, then tumbled by 33 bps to 131.32% in 2023, then jumped by 90 bps to 12.57% in 2025.
• Business Quant data shows MNPR's Return on Capital Employed at 12.57% in Q3 2025, 18.57% in Q2 2025, and 131.32% in Q3 2023.